sitefansalaran International News

The Saudi Arabia E-Pharmacy Market was valued at USD 923.56 Million in 2024 and is projected to reach USD 2.10 Billion by 2030, rising at a CAGR of 14.76%. The market is witnessing robust growth due to increased internet and smartphone usage, making healthcare more accessible via digital platforms. Consumers are shifting towards online pharmacies for prescription and over-the-counter medications, drawn by convenience and product availability. The rise in chronic diseases such as diabetes and hypertension further drives the need for reliable pharmaceutical access. Government initiatives promoting digital health, coupled with supportive e-commerce regulations, are enhancing sector growth. As awareness and digital engagement increase, the demand for e-pharmacy solutions is expanding rapidly across the Kingdom. Growing Internet Penetration Expanding internet usage is a key growth driver in Saudi Arabia's e-pharmacy sector. As of early 2024, the country recorded a 99.0% internet penetration rate, with over 36.84 million users. This widespread connectivity enables consumers to access e-pharmacy platforms easily through smartphones, supporting on-the-go purchasing and prescription management. The convenience of comparing prices, browsing a wide range of products, and receiving doorstep delivery has led more users to adopt online pharmacy services. The digital shift is further encouraged by the rise in e-commerce infrastructure and growing...

The U.S. could have saved up to $1.5 billion in the first year following approval of a drug if the price after rebates and discounts aligned with its benchmark, an analysis from an influential drug pricing watchdog showed on Thursday. The data from the Institute for Clinical and Economic Review, based on an analysis of 23 drugs previously reviewed by the research firm, comes as President Donald Trump has called for U.S. drug prices to match those paid in other high-income nations. ast month, Pfizer and Trump cut a deal to cut prices for drugs the company sells to the Medicaid program for low-income Americans and to ensure the U.S. would not pay more for new medicines than other high-income nations. U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, even as the government tries to rein in the costs. The review showed that aligning the prices with ICER's Health Benefit Price Benchmark could have saved about $1.3 billion to $1.5 billion in the first year post-approval alone. The benchmark suggests a price range that aligns fairly with the overall health benefits the treatment provides for patients over their lifetime.

Global CINV Existing and Pipeline Drugs Market, valued at USD 1.69 Billion in 2024, is projected to grow at a CAGR of 4.9% from 2025 to 2032, reaching approximately USD 2.49 Billion. Global CINV Existing and Pipeline Drugs Market Overview: Innovative Antiemetic Therapies, Rising Cancer Prevalence, and Next-Generation Chemotherapy Support Driving Growth Global CINV Existing and Pipeline Drugs Market is rapidly evolving, driven by rising cancer prevalence and breakthrough antiemetic therapies such as Aloxi, Akynzeo, Emend, and Rolapitant. Increasing adoption of CINV pipeline drugs across hospitals, specialty clinics, and pharmacy channels, coupled with clinical advancements by key players like GSK, Helsinn, and Heron Therapeutics, is reshaping chemotherapy-induced nausea and vomiting management, presenting lucrative opportunities, heightened competition, and a forward-looking growth trajectory in supportive oncology care.

Medical diagnostics firm Hologic has agreed to be acquired by Blackstone and TPG in a deal valued at up to $18.3 billion, it said on Tuesday, marking one of the largest healthcare take-private transactions this year. The company, which specializes in women's health diagnostics, including breast and cervical cancer screening, has grappled with waning demand since the COVID-19 pandemic, as well as rising competition. Under the agreement, Blackstone and TPG will pay $76 apiece in cash to buy all outstanding Hologic shares, implying a premium of nearly 6% to the stock's last close. Hologic shares were up nearly 4% in early trading. They have gained 13.5% since Reuters reported last month that Blackstone and TPG revived their interest after intermittent talks between the parties over the past year. Shareholders are also eligible for a non-tradable right to receive up to $3 per share, contingent on certain global revenue goals for its breast health business in fiscal years 2026 and 2027, bringing the total potential payout to $79 per share. In May, the Financial Times reported that Hologic had rejected a $70 to $72 per share offer from the private equity firms. The offer seems "fair for all parties," BTIG analyst Ryan Zimmerman said on Tuesday,...

The World Health Organization (WHO) and the European Union (EU) announced today a new agreement to support the digital transformation of health systems and wider adoption of WHO’s Global Digital Health Certification Network (GDHCN) in sub-Saharan Africa. This EU–WHO partnership will improve pandemic preparedness and accelerate progress towards better health and well-being for all. The agreement was announced at the World Health Summit 2025 by Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data; Dr Mohamed Yakub Janabi, WHO Regional Director for Africa; and Mr Martin Seychell, Deputy Director-General of the European Commission Directorate-General for International Partnerships. The GDHCN is a global system that enables countries to securely and reliably verify nationally approved digital health credentials across borders. The system builds on the European Union Digital COVID Certificate (EU DCC), which facilitated verification of vaccination, testing and recovery certification for international travelers connecting 76 countries and territories. However, only four countries from the WHO African Region—Benin, Cabo Verde, Seychelles and Togo—were able to join the EU DCC network. Since its transfer to the WHO in 2023, the GDHCN has shown strong potential to support the digitization of the International Certificate of Vaccination or Prophylaxis (ICVP), commonly known as the...

The Ministry of Human Resources and Social Development, in collaboration with the Ministry of Health of Saudi Arabia, has announced the implementation of the second phase of the decision to increase Saudization rates for four health professions within the private sector. The decision which comes into effect on Oct. 17, 2025, in line with the approved professional definitions and classifications. Under the new regulation, clinical nutrition and physical therapy professions are required to achieve an 80 percent Saudization rate, medical laboratories 70 percent, and radiology 65 percent. The minimum salary has been set at SR.7,000 for specialists and SR.5,000 for technicians. The decision applies to all private healthcare facilities across the Kingdom. The Ministry of Human Resources and Social Development has published procedural guidelines on its official website, outlining implementation details and Saudization ratios. It also urged establishments to comply with the decision to avoid regulatory penalties. The initiative builds on previous efforts to nationalize health professions, with the Ministry of Health supervising implementation to ensure alignment with labor market requirements. Private sector institutions will receive support and incentives through the human resources system, including recruitment assistance, training, qualification, employment sustainability, and priority access to Saudization and Human Resources Development Fund (HADAF) programmes. The decision aims...

World Osteoporosis Day, marked on October 20th each year, is a prime time to put the spotlight on osteoporosis. Below, read about this year’s campaign theme, and how you can get involved and support the campaign in a number of ways. ABOUT THE 2025 WORLD OSTEOPOROSIS DAY CAMPAIGN "It’s Unacceptable!" puts the spotlight on the persistent and preventable crisis in osteoporosis care. Despite affecting over 500 million people worldwide, osteoporosis remains severely underdiagnosed and undertreated—especially among those who have already sustained fragility fractures. Shockingly, up to 80% of patients with osteoporotic fractures receive no follow-up diagnosis or treatment. The consequences are devastating: chronic pain, disability, loss of independence, increased risk of future fractures, and premature death. Families, healthcare systems, and economies also shoulder the heavy burden of this neglect. The campaign demands an end to the neglect in prevention and care, and urgent policy action. At a time when effective diagnostic tools, treatments, and programmes like Fracture Liaison Services exist, the continued inaction is indefensible. With aging populations and fracture rates rising, osteoporosis must be prioritized across all stages of life—from prevention in youth to post-fracture care. "It’s Unacceptable!" calls on the public, healthcare providers, and health authorities to close the treatment gap,...

German biotech firm Tubulis said on Wednesday it had raised 308 million euros ($358 million) in its biggest financing round to date, contributing to a total of 495 million euros earmarked for advancing its research into targeted cancer therapies. Tubulis is developing targeted cancer treatment, specifically antibody-drug conjugates often referred to as “guided missiles,” which deliver chemotherapy directly to cancer cells while minimizing harm to healthy tissue. The market for these treatments is projected to reach $31 billion by 2030 based on currently approved drugs and could expand further, analysts at TD Cowen estimated. The financing signals that investors continue to think of such targeted therapies as a lucrative market, despite a prolonged period of tight financing in the biotech industry. “It’s a very competitive space, and the reason why it’s competitive is because this format is really providing benefit for patients,” said Tubulis CEO Dominik Schumacher. Schumacher said the funds will be used to test the company’s lead product – known as TUB-040 – in earlier lines of therapy and additional cancers. The drug binds to NaPi2b, a protein found in certain cancer cells, and is being tested as a treatment for platinum-resistant ovarian cancer and a common form lung cancer. Data from its ovarian...

A coalition of 15 U.S. state governors representing more than a third of the country's population has launched a new bipartisan alliance on Wednesday, aimed at improving public health coordination and emergency preparedness. The Governors Public Health Alliance will serve as a hub for governors and public health officials to share best practices, exchange data and collaborate on emergency response, vaccine policy and other technical issues, according to a joint statement from the coalition. The alliance of mostly Democratic states and territories comprises Colorado, California, Connecticut, Delaware, Hawaii, Illinois, Maryland, Massachusetts, New Jersey, New York, North Carolina, Oregon, Rhode Island, Washington and Guam. "While Donald Trump and RFK Jr. turn their backs on public health, Governors are stepping up to make sure our residents have the health care they need and deserve," Massachusetts Governor Maura Healey said. Severe budget reductions due to current and proposed federal cuts and funding pullbacks under the Trump administration have put public health at risk, the governors said. "Democrat-led states that imposed unscientific school closures, toddler mask mandates, and vaccine passports during the COVID era are the ones who destroyed public trust in public health," U.S. Department of Health and Human Services spokesperson Andrew Nixon said in a statement...

Britain's competition regulator proposed sweeping reforms to the country's $8 billion veterinary services market on Wednesday, saying pet owners often lack clear information on prices and overpay for medicines. However, the Competition and Markets Authority's provisional findings from a review of the sector were broadly as expected and did not include any negative surprises, analysts said, alleviating uncertainty that has pressured shares of vet services groups. Shares of CVS Group (CVSG.L), opens new tab, which operates about 470 veterinary practices across the UK and Australia and was one of six large veterinary groups named in the CMA's investigation, soared as much as 18% in early trade in London. Pets At Home (PETSP.L), opens new tab, which was also named as one of the large vet groups, rose as much as 4.5%. The CMA said pet owners pay about 17% more on average at large veterinary chains than at independent clinics, with average prices across the sector surging 63% between 2016 and 2023, and far outpacing inflation. The regulator's proposed measures include requiring vet businesses to publish comprehensive price lists, creating a price comparison website and capping prescription fees at 16 pounds. "Pet owners are often left in the dark, not knowing whether their practice...